PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

623 articles indexed across 24 specialties, each reviewed by a licensed pharmacist before publication.

⭐ Featured free samples

Three of our best full deep-analysis reports: hand-picked, free to read in full, no subscription required.

🔓 Free Sample
Nephrology / Renal Pharmacy ConfirmatoryGrade: Moderate

Finerenone Outperforms Spironolactone for Cardiorenal Protection in Moderate CKD

Finerenone emerges as the safer choice for CKD patients.

Read Free →
🔓 Free Sample
Neurology / Neuropharmacology ConfirmatoryGrade: Low

Tenecteplase Shortens Stroke Treatment and Transfer Times

Tenecteplase speeds up stroke thrombolysis compared to alteplase.

Read Free →
🔓 Free Sample
Rheumatology / Immunology ConfirmatoryGrade: Moderate

EULAR 2025 Streamlines Rheumatoid Arthritis DMARD Management to Nine Recommendations

New EULAR guidelines redefine RA management with DMARDs.

Read Free →
Showing 90 from 1 topic.Sort: Newest | Oldest
ATTLAS Quality of Life: Four-Drug Regimen Shows No Detectable Global Decline
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

Assessing QoL in lung cancer: Atezolizumab plus bevacizumab shines despite chemo challenges.

Anti-CD38 Quadruplets Lead MRD Rankings; Transplant Benefit Remains Unproven
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

Anti-CD38 regimens excel in achieving MRD negativity in myeloma.

Pertuzumab Dual Blockade Holds Up; Denosumab, Atezolizumab, Bevacizumab Add Little in HER2+ Disease
Analysis Oncology Pharmacy Confirmatory Grade: Moderate

Pertuzumab shows promise in treating aggressive HER2-positive breast cancer.

Dirozalkib Halves Progression Risk Versus Crizotinib in First-Line ALK-Positive NSCLC
Analysis Oncology Pharmacy Confirmatory Grade: Moderate

Dirozalkib shows superior efficacy to crizotinib in ALK-positive NSCLC.

Primary Endocrine Therapy vs Surgery in Older ER-Positive Breast Cancer: Biology Defines Candidates
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

No survival difference found between endocrine therapy and surgery in older breast cancer patients.

ICI Rechallenge After irAEs: One in Five Face Grade 3 or Higher Toxicity
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low

Rechallenging ICIs after adverse events shows high toxicity but promising disease control.

Chemoimmunotherapy in Early TNBC: Higher pCR, Fragile Survival Signal, Added Toxicity
★ Editor's Pick Analysis Oncology Pharmacy Confirmatory Grade: Low

ICIs and chemotherapy boost outcomes in early-stage TNBC.

Perioperative Tislelizumab Preserves Quality of Life and Eases Chest Pain, Cough in NSCLC
Analysis Oncology Pharmacy Confirmatory Grade: Moderate

Tislelizumab improves lung cancer patients' quality of life by reducing symptoms.

Perioperative Pembrolizumab in Resectable HNSCC: Ten-Year Evidence Review
Analysis Oncology Pharmacy Confirmatory Grade: Moderate

Pembrolizumab shows promise in perioperative treatment of resectable HNSCC.

Pooled PD-1/PD-L1 Cervical Cancer Meta-Analysis Shows OS Benefit, With Overlap Concerns
★ Editor's Pick Analysis Oncology Pharmacy Confirmatory Grade: Moderate

PD-1 inhibitors extend survival in metastatic cervical cancer.

Fewer Versus More Neoadjuvant Chemoimmunotherapy Cycles in Resectable Esophageal Squamous Cell Carcinoma
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low

Neoadjuvant cycles in esophageal cancer: flexibility or necessity?

Two Versus Three Induction Cycles in Nasopharyngeal Carcinoma: Equal Survival, More Toxicity
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low

Two chemo cycles reduce toxicity in nasopharyngeal cancer.

Nivolumab Plus Chemotherapy in Gastric Cancer Patients Aged 75 and Older: Real-World Feasibility
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Also in Geriatrics

Can older gastric cancer patients benefit from nivolumab plus chemotherapy?

One-Hour Antibiotic Rule Not Supported in Post-HSCT Neutropenic Fever
Analysis Infectious Disease / Antimicrobials Hypothesis-generating Grade: Low
Also in Oncology

Does the one-hour rule for antibiotics matter in stem cell transplants?

Second-Line HCC After TKI Failure: Efficacy Versus Toxicity Network Analysis
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Also in Gastroenterology / Hepatology

Pembrolizumab outshines others in post-TKI hepatocellular carcinoma treatment.